Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, has announced the pricing of an underwritten offering of 37,931,035 shares of its common stock at a price of US$2.90 per share. The gross proceeds from this offering are expected to be approximately US$110 million, before deducting the underwriting discount and commissions and estimated offering expenses payable by Allogene.
Latham & Watkins LLP represented the sole book-running manager in the offering, with a capital markets team led by Orange County partner Shayne Kennedy and Bay Area partner Phillip Stoup, with associates Tess Bloom and Taimi Jacobson. Advice was also provided on IP matters by Bay Area partner Judith Hasko, with associate Patrick Chew.
